From the Wall Street Journal today:
""We learned from HIV that we have to react aggressively to every next potential threat," says Michael Busch, director of the Blood Systems Research Institute in San Francisco and a member of a federally funded group studying whether the retrovirus XMRV, which has been linked to chronic fatigue syndrome, poses a threat to the blood supply.""
New Threats to U.S. Blood Supply
I notice they mention INTERCEPT by Cerus.
"The FDA declined to approve Intercept in the U.S. after a 2003 clinical trial showed a slight risk of a respiratory injury from blood treated with the system. Cerus Chief Medical Officer Laurence Corash says that in more than 75,000 transfusions in Europe there hasn't been any increased incidence of lung injuries with Intercept-treated platelets. The FDA doesn't accept European data. But Dr. Corash says the company is discussing "requirements for the size of a new clinical trial with the FDA, as well as preparing an alternative clinical study approach."
Since there was a successful trial of inactivating XMRV recently (Collaboration between WPI and Cerus), hopefully they will reconsider and look again at INTERCEPT.
˙·٠•●♥ ƹ̵̡ӝ̵̨̄ʒ ♥●•٠·˙
No comments:
Post a Comment